ENTRY       hsa05020                    Pathway
NAME        Prion diseases - Homo sapiens (human)
DESCRIPTION Prion diseases, also termed transmissible spongiform encephalopathies (TSEs), are a group of fatal neurodegenerative diseases that affect humans and a number of other animal species. The etiology of these diseases is thought to be associated with the conversion of a normal protein, PrPC, into an infectious, pathogenic form, PrPSc. The conversion is induced by prion infections (for example, variant Creutzfeldt-Jakob disease (vCJD), iatrogenic CJD, Kuru), mutations (familial CJD, Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia (FFI)) or unknown factors (sporadic CJD (sCJD)), and is thought to occur after PrPC has reached the plasma membrane or is re-internalized for degradation. The PrPSc form shows greater protease resistance than PrPC and accumulates in affected individuals, often in the form of extracellular plaques. Pathways that may lead to neuronal death comprise oxidative stress, regulated activation of complement, ubiquitin-proteasome and endosomal-lysosomal systems, synaptic alterations and dendritic atrophy, corticosteroid response, and endoplasmic reticulum stress. In addition, the conformational transition could lead to the lost of a beneficial activity of the natively folded protein, PrPC.
CLASS       Human Diseases; Neurodegenerative diseases
PATHWAY_MAP hsa05020  Prion diseases
DISEASE     H00061  Prion disease
ORGANISM    Homo sapiens (human) [GN:hsa]
GENE        5621  PRNP; prion protein [KO:K05634]
            3309  HSPA5; heat shock protein family A (Hsp70) member 5 [KO:K09490]
            4684  NCAM1; neural cell adhesion molecule 1 [KO:K06491]
            4685  NCAM2; neural cell adhesion molecule 2 [KO:K06491]
            3915  LAMC1; laminin subunit gamma 1 [KO:K05635]
            6647  SOD1; superoxide dismutase 1 [KO:K04565] [EC:1.15.1.1]
            10963  STIP1; stress induced phosphoprotein 1 [KO:K09553]
            5566  PRKACA; protein kinase cAMP-activated catalytic subunit alpha [KO:K04345] [EC:2.7.11.11]
            5567  PRKACB; protein kinase cAMP-activated catalytic subunit beta [KO:K04345] [EC:2.7.11.11]
            5568  PRKACG; protein kinase cAMP-activated catalytic subunit gamma [KO:K04345] [EC:2.7.11.11]
            581  BAX; BCL2 associated X, apoptosis regulator [KO:K02159]
            2534  FYN; FYN proto-oncogene, Src family tyrosine kinase [KO:K05703] [EC:2.7.10.2]
            100506742  CASP12; caspase 12 (gene/pseudogene) [KO:K04741] [EC:3.4.22.-]
            727  C5; complement C5 [KO:K03994]
            729  C6; complement C6 [KO:K03995]
            730  C7; complement C7 [KO:K03996]
            731  C8A; complement C8 alpha chain [KO:K03997]
            732  C8B; complement C8 beta chain [KO:K03998]
            733  C8G; complement C8 gamma chain [KO:K03999]
            735  C9; complement C9 [KO:K04000]
            712  C1QA; complement C1q A chain [KO:K03986]
            713  C1QB; complement C1q B chain [KO:K03987]
            714  C1QC; complement C1q C chain [KO:K03988]
            4851  NOTCH1; notch receptor 1 [KO:K02599]
            5604  MAP2K1; mitogen-activated protein kinase kinase 1 [KO:K04368] [EC:2.7.12.2]
            5605  MAP2K2; mitogen-activated protein kinase kinase 2 [KO:K04369] [EC:2.7.12.2]
            5594  MAPK1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
            5595  MAPK3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
            2002  ELK1; ETS transcription factor ELK1 [KO:K04375]
            1958  EGR1; early growth response 1 [KO:K09203]
            6352  CCL5; C-C motif chemokine ligand 5 [KO:K12499]
            3552  IL1A; interleukin 1 alpha [KO:K04383]
            3553  IL1B; interleukin 1 beta [KO:K04519]
            3569  IL6; interleukin 6 [KO:K05405]
            3303  HSPA1A; heat shock protein family A (Hsp70) member 1A [KO:K03283]
COMPOUND    C00027  Hydrogen peroxide
            C00575  3',5'-Cyclic AMP
            C02140  Corticosterone
REFERENCE   PMID:18245809
  AUTHORS   Kovacs GG, Budka H
  TITLE     Prion diseases: from protein to cell pathology.
  JOURNAL   Am J Pathol 172:555-65 (2008)
            DOI:10.2353/ajpath.2008.070442
REFERENCE   PMID:15695097
  AUTHORS   Campana V, Sarnataro D, Zurzolo C
  TITLE     The highways and byways of prion protein trafficking.
  JOURNAL   Trends Cell Biol 15:102-11 (2005)
            DOI:10.1016/j.tcb.2004.12.002
REFERENCE   PMID:14661267
  AUTHORS   Nunziante M, Gilch S, Schatzl HM
  TITLE     Prion diseases: from molecular biology to intervention strategies.
  JOURNAL   Chembiochem 4:1268-84 (2003)
            DOI:10.1002/cbic.200300704
REFERENCE   PMID:17051207
  AUTHORS   Caughey B, Baron GS
  TITLE     Prions and their partners in crime.
  JOURNAL   Nature 443:803-10 (2006)
            DOI:10.1038/nature05294
REFERENCE   PMID:18391177
  AUTHORS   Linden R, Martins VR, Prado MA, Cammarota M, Izquierdo I, Brentani RR
  TITLE     Physiology of the prion protein.
  JOURNAL   Physiol Rev 88:673-728 (2008)
            DOI:10.1152/physrev.00007.2007
REFERENCE   PMID:11592845
  AUTHORS   Chiesa R, Harris DA
  TITLE     Prion diseases: what is the neurotoxic molecule?
  JOURNAL   Neurobiol Dis 8:743-63 (2001)
            DOI:10.1006/nbdi.2001.0433
REFERENCE   PMID:10398674
  AUTHORS   Harris DA
  TITLE     Cellular biology of prion diseases.
  JOURNAL   Clin Microbiol Rev 12:429-44 (1999)
REFERENCE   PMID:15528202
  AUTHORS   Marella M, Gaggioli C, Batoz M, Deckert M, Tartare-Deckert S, Chabry J
  TITLE     Pathological prion protein exposure switches on neuronal mitogen-activated protein kinase pathway resulting in microglia recruitment.
  JOURNAL   J Biol Chem 280:1529-34 (2005)
            DOI:10.1074/jbc.M410966200
REFERENCE   PMID:15611724
  AUTHORS   Mallucci G, Collinge J
  TITLE     Rational targeting for prion therapeutics.
  JOURNAL   Nat Rev Neurosci 6:23-34 (2005)
            DOI:10.1038/nrn1584
REFERENCE   PMID:12850426
  AUTHORS   Hegde RS, Rane NS
  TITLE     Prion protein trafficking and the development of neurodegeneration.
  JOURNAL   Trends Neurosci 26:337-9 (2003)
            DOI:10.1016/S0166-2236(03)00143-7
REFERENCE   PMID:17085779
  AUTHORS   Fasano C, Campana V, Zurzolo C
  TITLE     Prions: protein only or something more? Overview of potential prion cofactors.
  JOURNAL   J Mol Neurosci 29:195-214 (2006)
            DOI:10.1385/JMN:29:3:195
REFERENCE   PMID:14705136
  AUTHORS   Roucou X, Gains M, LeBlanc AC
  TITLE     Neuroprotective functions of prion protein.
  JOURNAL   J Neurosci Res 75:153-61 (2004)
            DOI:10.1002/jnr.10864
REFERENCE   PMID:15890824
  AUTHORS   Novakofski J, Brewer MS, Mateus-Pinilla N, Killefer J, McCusker RH
  TITLE     Prion biology relevant to bovine spongiform encephalopathy.
  JOURNAL   J Anim Sci 83:1455-76 (2005)
            DOI:10.2527/2005.8361455x
REFERENCE   PMID:18558863
  AUTHORS   Aguzzi A, Baumann F, Bremer J
  TITLE     The prion's elusive reason for being.
  JOURNAL   Annu Rev Neurosci 31:439-77 (2008)
            DOI:10.1146/annurev.neuro.31.060407.125620
REFERENCE   PMID:15342004
  AUTHORS   Mabbott NA
  TITLE     The complement system in prion diseases.
  JOURNAL   Curr Opin Immunol 16:587-93 (2004)
            DOI:10.1016/j.coi.2004.07.002
KO_PATHWAY  ko05020
///
